|Mr. Mark J. Gergen J.D.||President, CEO & Chairman||920.74k||N/A||1963|
|Mr. Harry J. Leonhardt Esq., J.D.||General Counsel, Chief Compliance Officer & Corporate Secretary||630.23k||N/A||1957|
|Mr. Brent Warner||President of Gene Therapy||835.93k||N/A||1984|
|Ms. Johanna M. Mylet CPA||Chief Financial Officer||N/A||N/A||1987|
|Mr. Loren Wagner||Senior Vice President of Global Operations||N/A||N/A||N/A|
|Ms. Kristin Martin||Chief People & Administration Officer||N/A||N/A||N/A|
|Sarah Thailing||Senior Director of Corporate Communications & IR||N/A||N/A||N/A|
|Dr. Devon J. Shedlock Ph.D.||Chief Scientific Officer of Cell Therapy||N/A||N/A||N/A|
|Ms. Lisa Portale||Senior Vice President of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Jeffrey W. Winkelman J.D., Ph.D.||Senior VP & Chief Patent Counsel||N/A||N/A||N/A|
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.